Roche's key drugs lift sales by 7% at CER despite FX headwinds. The company expects mid-single digit sales growth in 2026.
Earnings Call Insights: Qiagen N.V. (NYSE:QGEN) Q4 2024 Thierry Bernard, CEO, highlighted that Qiagen surpassed its Q4 2024 ...
SOUTH SAN FRANCISCO, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation of ...
CALGARY, AB, June 15, 2023 /CNW/ - The Canada Energy Regulator (CER) has improved the methodology for how companies fund future pipeline abandonment. This will enhance our ability to ensure that ...